Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment.

Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia (ALL). Considering its favorable safety and activity in advanced ALL, blinatumomab as a targeted immunotherapy is fast gaining a frontline position in the ALL treatment paradigm. There have been multiple completed and ongoing studies showing significant promise with improved response rates and survival outcomes and decreased treatment toxicity and need for multi-agent chemotherapy regimens. The early use of blinatumomab has established success in Ph-negative and Ph-positive B-ALL, and this has extended to older adults with ALL who have historically had substantially inferior outcomes compared to their pediatric and young adult counterparts. Herein we will review the current data describing the early use of blinatumomab in newly diagnosed adults with B-cell ALL and future directions.

Informations de copyright

Copyright © 2023 Pourhassan, Agrawal, Pullarkat and Aldoss.

Déclaration de conflit d'intérêts

VP has served on advisory boards for AbbVie and Jazz Pharmaceuticals and is a member of the speakers bureau for Jazz Pharmaceuticals, Amgen, Novartis, and AbbVie. IA serves on advisory boards for Amgen, Takeda, Pfizer, Sobi, Jazz Pharma, Kite Pharmaceuticals, AbbVie, and Agios Pharmaceuticals and is a consultant for Pfizer and Amgen, with research support from MacroGenics and Abbvie. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.